Traxon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Traxon

Property Description
Active Ingredient (INN) Trazodone Hydrochloride
Primary Form Oral Tablets (Standard and Extended-Release)
Pharmacological Class Serotonin-Antagonist-and-Reuptake-Inhibitor (SARI)
General Purpose Treatment of Major Depressive Disorder (MDD)
Origin / Status Synthetic Compound / Prescription Only (Rx)

Essential Identity and Therapeutic Class

Traxon is the proprietary name for a prescription-only medication containing the active ingredient Trazodone Hydrochloride. It is formally classified as a Serotonin-Antagonist-and-Reuptake-Inhibitor (SARI), a distinct category of antidepressant. This medicine is clinically recognized for its established role in treating Major Depressive Disorder (MDD) and is a tool for long-term pharmacological support in patients whose symptoms are severe enough to interfere with daily life.

Composition and Origin: Unique Features and Forms

Traxon is manufactured as oral tablets and is a fully synthetic compound, meaning its active molecule is created through precise chemical synthesis in a laboratory, ensuring consistent quality and potency. A key feature of this medication is its availability in both immediate-release and specialized extended-release formulations, which are designed to manage the drug's concentration in the body over a longer period. This formulation difference contributes to its versatile use in clinical settings.

General Therapeutic Purpose

The fundamental general therapeutic purpose of Traxon is the management of symptoms associated with Major Depressive Disorder (MDD), which is its primary regulatory indication. The objective of this therapy is to help restore the balance of certain neurochemicals in the brain, thereby assisting in the stabilization of a patient's mood and improving overall functioning and quality of life.

Regulatory References

  1. Trazodone - StatPearls - NCBI Bookshelf

What side effects are possible with Traxon?

Possible side effects and safety information

The safety profile for Traxon (Trazodone Hydrochloride) is officially documented by regulatory agencies, detailing adverse reactions by frequency and affected body systems. The most frequently reported adverse reactions, classified as Very Common, affect the Central Nervous System (CNS) and include drowsiness, dizziness, headache, and dry mouth. Other Common effects include fatigue, blurred vision, and orthostatic hypotension (low blood pressure upon standing).


Serious Adverse Reactions and Safety Constraints

Official labeling specifically highlights the risk of several serious adverse reactions, which are rare but clinically significant. These include Priapism (a prolonged, painful erection), Serotonin Syndrome (a potentially life-threatening condition associated with mental status changes), and severe cardiac arrhythmias (such as QT prolongation and Torsade de Pointes).

Safety notes specify that the risk of suicidal thoughts and behaviors is increased in young adults (ages 18 to 24) and children, particularly during the initial months of treatment and following dose changes. Use in patients under 18 years is generally not recommended.

Population and Time-Related Safety

The safety profile includes specific considerations for certain patient groups. Older adults may be at an increased risk for orthostatic hypotension, which can lead to falls and hip fractures. The label also notes that the risk of Priapism appears to be greatest during the first month of treatment. Furthermore, the medicine is not recommended for use during the initial recovery phase following a myocardial infarction.

Overdose and Emergency Response

Overdose and when to seek help

Officially documented information regarding Traxon (Trazodone Hydrochloride) overdose establishes a range of potential clinical manifestations, requiring specific emergency responses. The most frequently reported signs of an overdose event include marked drowsiness, vomiting, dizziness, and hypotension (low blood pressure), stemming from Central Nervous System (CNS) effects. Regulatory documents further describe more severe manifestations affecting both the CNS and the cardiovascular system.

Documented severe outcomes may include seizures, respiratory arrest, and coma. The medication is also associated with the risk of cardiac arrhythmias, such as QT prolongation, necessitating continuous cardiac monitoring in a medical setting. A specific, life-threatening risk is the potential for death, documented primarily when Trazodone is ingested concurrently with other CNS depressant substances, such as alcohol.

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Specifically, emergency services should be contacted if the affected individual collapses, experiences a seizure, or has difficulty breathing. Immediate medical evaluation is also required for the severe, time-critical event of Priapism (a prolonged erection). As no specific antidote is known for Trazodone overdose, official management protocols involve symptomatic and supportive treatment, which may include procedures like gastric lavage or the administration of activated charcoal.

Therapeutic Uses of Traxon

What Traxon Treats: Main Uses and Benefits

Traxon (Trazodone Hydrochloride) is a prescription medication relevant in contexts involving symptom management related to mood, sleep, and anxiety symptoms often associated with clinical depression. The primary purpose of its use is to offer symptomatic relief, which may support general well-being and assist with maintaining functional stability.


The medication is commonly used across conditions presenting with acute episodes of Major Depressive Disorder (MDD). It is also applied across domains where additional symptomatic support is needed to help with sleep disturbances, inner tension, and psychomotor agitation. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, and may assist with maintaining functional stability during symptomatic periods. This approach focuses on easing the overall symptom load when individuals experience symptoms that interfere with daily functioning.

“This medication is commonly used to help with groups of symptoms that create noticeable functional strain, supporting the patient during difficult episodes.”

Quick Fact: Support for Sleep Disturbances and Anxiety Traxon is commonly used to help manage symptom clusters of sleep difficulties and restlessness that frequently occur alongside low mood, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Traxon (Trazodone) is formally indicated for use in adults for the treatment of Major Depressive Disorder (MDD). Official regulatory documents define specific populations who must not use the medicine and those for whom use is restricted or requires caution.


Official Eligibility Classifications

Classification Population Restriction Regulatory Basis (Example)
Contraindicated Known hypersensitivity to trazodone; Use with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI); Patients in the initial recovery phase following a myocardial infarction (acute MI). FDA / EMA SmPC
Use Not Established Pediatric patients (under 18 years of age). FDA / EMA SmPC
Caution Required Geriatric patients (older adults); Patients with severe hepatic or renal impairment; Patients with pre-existing cardiac disease or a history of priapism. FDA / EMA SmPC

Age-Related Eligibility: Safety and efficacy have not been established for children and adolescents under 18 years. Use is generally permitted in older adults, but regulatory labels advise caution due to potentially increased susceptibility to certain side effects.

Pregnancy and Lactation Status: Traxon use is generally not recommended during pregnancy, especially the first and third trimesters, unless the benefit clearly justifies the potential risk. Trazodone is known to be excreted in breast milk, requiring a careful assessment during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Traxon (Trazodone Hydrochloride) specifies several documented interaction patterns, primarily categorized as pharmacokinetic and pharmacodynamic.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, is formally contraindicated due to the increased risk of Serotonin Syndrome. A mandatory 14-day separation is required when switching between Trazodone and an MAOI. Certain drugs that prolong the QT interval are also listed as contraindicated combinations.


Pharmacokinetic and Pharmacodynamic Interactions

Pharmacokinetic Interactions primarily involve the CYP3A4 enzyme. Strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) are documented to substantially increase Trazodone plasma concentration, while inducers (e.g., Carbamazepine, St. John’s Wort) may cause a significant decrease in exposure.

Pharmacodynamic Interactions include additive effects with other serotonergic drugs (increasing Serotonin Syndrome risk) and with Central Nervous System (CNS) depressants, including alcohol, which can enhance sedative effects. Co-administration with antihypertensive drugs may potentiate hypotensive effects. Use with drugs that affect coagulation (e.g., NSAIDs, Warfarin) is associated with an increased risk of bleeding.

Mechanism of Action

How Traxon Works

Traxon operates through a dual mechanistic profile classified as a Serotonin-Antagonist-and-Reuptake-Inhibitor (SARI). Its action involves two primary domains: serotonergic modulation and CNS arousal inhibition.

First, it moderately inhibits the Serotonin Transporter ( SERT), increasing synaptic serotonin ( 5-HT), while simultaneously acting as an antagonist of the postsynaptic 5-HT2A receptor. This targeted molecular sequence redirects 5-HT signaling, contributing to the functional adjustment of neural circuits related to emotional processing.

Second, the molecule exerts rapid physiological effects through high binding affinity for the H1 (histamine) receptor and the alpha1-adrenergic receptor. Antagonism of these receptors interrupts wakefulness signals, initiating a rapid inhibition of wakefulness pathways.

These two mechanisms demonstrate concentration-dependent dominance. The inhibition of H1 and alpha1 receptors occurs at lower plasma concentrations, whereas the SERT inhibition necessary for full serotonergic network modulation requires higher concentrations, dictating the sequencing of the drug's physiological impact.

Dosage and Administration Information

Administration Route and Dosing

Traxon (Trazodone Hydrochloride) is administered exclusively by the oral route as either an immediate-release (IR) tablet or an extended-release (ER) tablet. The general usage pattern is fundamentally determined by the formulation, which affects frequency and intake conditions.

For the immediate-release form, the adult starting dosage is typically 150 mg per day, usually taken in divided doses. The total daily amount is subject to gradual increase (titration) over time, adjusting the dose by increments of up to 50 mg every three to four days, to reach a therapeutic maintenance range. This range commonly extends between 150 mg and 400 mg per day, though the maximum dose for outpatients is officially capped at 400 mg daily.


Timing and Specific Conditions

A key principle of proper administration involves timing in relation to food. The IR formulation is often advised to be taken shortly after a meal or light snack. Conversely, the ER formulation is typically administered once daily (q.d.), frequently at bedtime, and often under conditions that require an empty stomach. The IR dose is commonly split so that the largest portion is consumed at night to align with the required schedule.

Proper administration protocols mandate that the extended-release tablet must not be crushed, split, or chewed to preserve its controlled delivery mechanism. Furthermore, a lower initial dose and cautious adjustment are necessary when prescribing to older or frail adult populations. Discontinuation of treatment must always involve a gradual dose reduction (tapering).

Recent Clinical Evidence

Research evidence / Overview of Studies for Traxon

The research evidence for Traxon (Trazodone Hydrochloride) is primarily structured around its primary regulatory indication, Major Depressive Disorder (MDD), and the study of associated symptoms. The studies primarily consist of short-term randomized controlled trials (RCTs), comparative trials, and systematic reviews that monitor symptom changes in defined patient groups.


Evidence for Use in Major Depressive Disorder (MDD)

The core evidence related to the medication in Major Depressive Disorder is derived from short-term randomized controlled trials (RCTs). These studies were designed for use in research exploring how symptoms change over time by comparing the medication against placebo or other active antidepressant comparators in adult populations. Researchers primarily used standardized rating scales to measure the intensity of depression symptoms and monitor response (a predefined degree of symptom reduction) and remission (meeting criteria for minimal symptoms) in observed participants.

Studies report how symptoms evolved in the observed populations during the acute treatment phase, which typically spans about 6 to 12 weeks. Findings describe patterns observed in the studies related to changes in depression scale scores. The structure of the available evidence for MDD is generally graded as High for short-term symptom monitoring.


Research Evidence on Related Sleep Disturbances

Traxon was also evaluated in research focusing on sleep difficulties, restlessness, and inner tension, outcomes capturing phases of heightened symptom activity often studied in individuals with MDD. These studies frequently appear as secondary assessments within the main depression trials or in dedicated short-term sleep studies.

Studies report how symptoms evolved in the observed populations, with findings describing patterns related to changes in both subjective and objective sleep metrics, usually over short time intervals. The evidence structure for the sleep-related outcomes is generally graded as Moderate, as many sleep assessments are derived from secondary analyses. The evidence is limited regarding long-term outcomes when focusing only on sleep metrics, and data are still emerging regarding the consistent effects across all sleep stages.


Areas of Research Uncertainty and Gaps

While there is a foundation of evidence, the research also highlights areas where more data are needed. Long-term effects are not fully established for all outcomes, particularly those related to functional recovery and quality of life over multiple years. Data for certain groups remain insufficient, especially for children, adolescents, or pregnant populations. The research does not determine whether an individual will experience similar outcomes to the group patterns observed in the trials.

Key Studies & References

  1. Label: TRAZODONE HYDROCHLORIDE tablet - DailyMed (FDA-mandated labeling for Trazodone)
  2. Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder

Frequently Asked Questions (FAQ)

Common questions about Traxon (FAQ)

Q: How quickly should someone expect Traxon to start working?

The maximum concentration of the immediate-release form in the bloodstream is typically reached within one hour of taking it. However, official studies indicate that the full therapeutic effect for Major Depressive Disorder (MDD) may take several weeks of treatment to fully assess. Initial effects may be noticed sooner, but full therapeutic response takes time.

Q: What signs indicate a serious reaction to Traxon?

Official product information details serious reactions that require immediate medical attention. These include signs of Serotonin Syndrome (such as confusion, agitation, high fever, or severe muscle stiffness), any symptoms related to heart problems (like fainting, chest pain, or a fast, irregular heartbeat), and a prolonged, painful erection (Priapism) lasting longer than six hours. The documentation advises seeking immediate medical attention if any serious reaction signs are observed.

Q: Are there any foods or drinks that should be avoided when taking Traxon?

Yes, the official regulatory profile notes specific interactions. Regulatory information indicates that grapefruit and grapefruit juice should generally be avoided because they can significantly increase the level of the medicine in the blood. This effect may increase the risk of experiencing adverse reactions.

Q: Can herbal supplements or vitamins affect how Traxon works?

The medication can interact with substances that affect the CYP3A4 enzyme in the body, which includes some herbal products like St. John’s Wort. These substances may either increase or decrease the medicine's effectiveness. Regulatory documents advise consulting a healthcare provider before combining this medication with other supplements or over-the-counter medicines.

Q: What does the FDA label say about Traxon's effectiveness?

According to the official regulatory documents, the medicine is indicated for the treatment of Major Depressive Disorder (MDD) in adults. This means the evidence for its use is grounded in studies focused on the symptoms associated with this condition.

Q: Is it true that Traxon affects liver function?

The medicine is extensively processed by a liver enzyme called CYP3A4. For this reason, official regulatory labels advise that caution is required when prescribing Traxon to patients who have existing severe hepatic (liver) impairment.

Q: Does Traxon cause changes in mood or behavior?

Regulatory information includes a boxed warning that antidepressants may increase the risk of suicidal thoughts and behaviors in young adults. The prescribing information stresses the importance of monitoring for clinical worsening or the emergence of new symptoms like agitation or extreme worry when starting treatment or changing the dose.

Q: Does Traxon affect driving or operating machinery?

Yes. Due to common side effects like drowsiness and dizziness, official safety warnings state that the medicine has the potential to impair judgment, thinking, and motor skills. Official warnings advise that caution should be used when driving or operating complex machinery.

Q: Is a specific diet required while taking Traxon?

No specific therapeutic diet is officially required. However, proper administration protocols specify that the immediate-release tablet should be taken shortly after a meal or light snack to help minimize the risk of side effects. Conversely, the extended-release form may be administered on an empty stomach.

Q: Is Traxon used to treat other conditions besides its primary indication?

Official regulatory documents state that the medicine is only approved for Major Depressive Disorder (MDD). Any other uses are considered off-label by regulatory bodies and are not addressed in the official prescribing information.

Q: How long do the effects of Traxon usually last?

Studies on how the body processes the medication show that the elimination half-life can vary significantly. It is generally reported to be between 4 and 15 hours for the immediate-release form and 9 to 13 hours for the extended-release form.

Q: Is Traxon a medication that requires long-term use?

Official guidelines do not mandate a maximum time limit for use. The regulatory label suggests that once an adequate response has been achieved, the dosage can be gradually reduced over time. The duration of treatment is determined by a healthcare provider based on therapeutic response.

Q: Do the side effects of Traxon usually go away over time?

Official patient resources note that some of the common side effects, such as dizziness, drowsiness, and dry mouth, may go away within a short period or a few days as the body adjusts to the medication. It is important that patients report any persistent or worsening side effects to their healthcare provider.

Q: Can Traxon cause weight gain?

The official list of adverse reactions from clinical trials documents that weight loss is actually one of the commonly reported effects. Weight gain has also been reported in clinical studies, but generally with a low incidence compared to other antidepressants.

Q: Does Traxon interact with common over-the-counter pain relievers?

Yes, the medicine has documented interactions with some over-the-counter pain relievers. Official warnings state that using Traxon with medications like aspirin or NSAIDs (Nonsteroidal Anti-inflammatory Drugs) may increase the risk of bleeding.

Q: What is the risk of dependence or addiction associated with Traxon?

The official regulatory classification states that the medicine is not a controlled substance. While it has a low potential for abuse or addiction, physical dependence may occur with regular use.

Q: Why do some people experience trouble sleeping when taking Traxon?

Trouble sleeping is not listed as a common side effect in regulatory documents; in fact, drowsiness is very common. The product label notes that due to this sedative effect, the major portion of the daily dose is often administered at bedtime.

Q: Is Traxon a controlled substance?

No, according to the official regulatory classification. Trazodone Hydrochloride is not considered a controlled substance under the U.S. Controlled Substances Act or equivalent regulatory body.

Q: What happens if a dose of Traxon is missed?

Official patient guidelines provide instructions for a missed dose. These instructions generally involve taking the dose as soon as it is remembered, unless it is almost time for the next scheduled dose. If this occurs, the missed dose is typically skipped, and patients are advised not to take two doses at once.

Q: Are there generic versions of Traxon available?

Yes. Traxon is the proprietary name, and the active ingredient, Trazodone Hydrochloride, is available in generic form. Generic drugs must meet the same quality and purity standards set by regulatory agencies.

Q: What is the difference between brand name Traxon and its generic?

Traxon is the brand name for the medicine, and its active ingredient is Trazodone Hydrochloride. The generic form contains the same active ingredient and must meet the same regulatory standards for strength, quality, and purity as the brand name product.

Q: Are there common reasons why Traxon might be discontinued?

Discontinuation is typically discussed with a healthcare provider if a patient experiences unmanageable side effects such as persistent drowsiness or orthostatic hypotension (dizziness upon standing). Stopping treatment may be necessary if a patient experiences any of the documented serious adverse reactions.

How should Traxon be stored and disposed of?

How to Store and Dispose of Traxon?

Official regulatory documents define strict requirements for storing and disposing of Traxon (Trazodone Hydrochloride) tablets to maintain product stability and ensure household safety.

Storage Requirements

Condition Requirement
Temperature Store at room temperature (15 C to 30 C / 59 F to 86 F) and keep from freezing.
Container/Protection Keep the medicine in its original container, tightly closed, and protect from light and excess moisture (e.g., do not store in the bathroom).
Safety Keep out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Traxon must be discarded according to official instructions. This generally requires using drug take-back programs or rendering the medicine unusable before disposal in household trash, consistent with local regulations. The medication must not be flushed down a toilet or sink unless directed by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Traxon found in:

A-Z Index: